Nitin Jain, MD, on Targeted Treatments and Tumor-Lysis Syndrome

Posted: Monday, September 30, 2019

What steps do you take to prevent tumor-lysis syndrome associated with targeted agents in CLL such as idelalisib, ibrutinib, and venetoclax?